Search clinical trials for: radioligand [18F]AZD4694

Total 2576 results

AstraZeneca

Completed

Positron Emission Tomography (PET) Study With [18F]AZD4694 and [11C]AZD2184, Candidate PET Ligands for Aβ Amyloid (PET)

Alzheimer's Disease

Sweden
AstraZeneca

Completed

To Compare Positron Emission Tomography (PET) Measurements of Fibrillar Amyloid Burden

Alzheimer's Disease

United States
CHDI Foundation, Inc.

Completed

Follow-up Measurement of Brain PDE10A Enzyme Levels in Huntington´s Disease Gene Expansion Carriers (LONGPDE10)

Huntington's Disease

Sweden, Denmark, Netherlands, Norway
Stanford University

Active, not recruiting

Reliability of [18F]-FTC-146 Brain Uptake in Healthy Controls (rSIG)

Healthy Controls

United States
University of Southern California
National Institute on Aging (NIA); Northern California Institute of Research... and other collaborators

Recruiting

Alzheimer's Disease Neuroimaging Initiative 4 (ADNI4)

Dementia | Alzheimer Disease | Mild Cognitive Impairment

United States, Canada
Duke University

Withdrawn

Risk Prediction for Alzheimer Dementia With Brain Imaging and Genetics

Traumatic Brain Injury | Posttraumatic Stress Disorder | Alzheimer Dementia

United States
Stanford University
University of Mississippi Medical Center

Completed

[18F]FTC-146 PET/MRI in Healthy Volunteers and in CRPS and Sciatica

Sciatica | Complex Regional Pain Syndrome

United States
MidLantic Urology
Blue Earth Diagnostics

Recruiting

Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management

Prostate Cancer

United States
CHDI Foundation, Inc.
Universitaire Ziekenhuizen KU Leuven

Terminated

iMagemHTT: FIH Evaluation of Novel Mutant Huntingtin PET Radioligands [¹¹C]CHDI-00485180-R and [¹¹C]CHDI-00485626

Huntington Disease

Belgium
AstraZeneca

Completed

An Open Positron Emission Tomography Study to Assess the Effects of Varying Mass of AZD4694 on Radioligand Binding Parameters in Healthy Volunteers and Patients With Alzheimer's Disease

Maximum Diagnostic Mass of [18Fluor]AZD4694

Sweden
AstraZeneca

Completed

Positron Emission Tomography (PET) Study With [11C]AZD2995 and [11C]AZD2184, Candidate PET Ligands for β Amyloid (PET)

Alzheimer´s Disease

Sweden
The First Affiliated Hospital of Xiamen University

Recruiting

Clinical Evaluation of 177Lu-AB-3PRGD2 in Various Solid Tumors With Integrin αvβ3 Positive Expression

Refractory Solid Tumor

China
AstraZeneca

Completed

Positron Emission Tomography (PET) Study With [11C]AZ12713580 to Determine Central mGluR5 Receptor Occupancy of AZD2066 (PET)

Healthy

Sweden
Merck Sharp & Dohme LLC

Completed

[18F]MK-6240 Positron Emission Tomography (PET) Tracer First-in-Human Validation Study (MK-6240-001)

Alzheimer's Disease | Amnestic Mild Cognitive Impairment
The First Affiliated Hospital of Xiamen University

Recruiting

Clinical Evaluation of 177Lu-DansyI-PSMA (LNC1011) in Patients With Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer, mCRPC

China
AstraZeneca

Completed

A Clinical Trial in Healthy Volunteers and Patients With Mild Asthma to Investigate a New Medicine (AZD4604) for the Treatment of Asthma

Asthma

United Kingdom
Massachusetts General Hospital
Cedars-Sinai Medical Center; ALS Association; The Methodist Hospital Research...

Completed

Imaging and BioFluid Biomarkers in Amyotrophic Lateral Sclerosis (TRACK-ALS)

Amyotrophic Lateral Sclerosis (ALS)

United States
Avid Radiopharmaceuticals

Completed

The Feasibility of Florbetapir Quantitation in Europe

Alzheimer's Disease

Netherlands
British Columbia Cancer Agency

No longer available

18F-FDOPA PET in Neuroendocrine Tumours

Thyroid Cancer, Medullary | Neuroblastoma | Pheochromocytoma | Carcinoid Tumor | Paraganglioma | Insulinoma

Canada
Avid Radiopharmaceuticals
Eli Lilly and Company

Completed

A Study of Florbetapir (18F) in Japanese Healthy Volunteers

Alzheimer's Disease

Japan
Avid Radiopharmaceuticals
Eli Lilly and Company

Completed

A Phase II Trial of Florbetapir (18F) Positron Emission Tomography (PET) Imaging in Japan of Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)

Mild Cognitive Impairment | Alzheimer's Disease

Japan
AstraZeneca
Quotient Sciences

Active, not recruiting

An ADME Study of [14C]AZD4604 and the Absolute Bioavailability of AZD4604

Asthma

United Kingdom
Frederick Daniel Grant
Dana-Farber Cancer Institute

Completed

FLT-PET Imaging of Brain Tumors in Children

Brain Neoplasms

United States
Avid Radiopharmaceuticals

Withdrawn

Evaluation of Electronic Florbetapir (18F) Interpretation Training in Japanese Physicians

Alzheimer's Disease

Japan
Markus Weber
University Hospital Inselspital, Berne; ETH Zurich

Not yet recruiting

Investigation of Cannabinoid 2-receptor Expression in the Brain and Spine of ALS-patients Compared to Healthy Controls With PET (18F-RoSMALS) (18F-RoSMALS)

Amyotrophic Lateral Sclerosis

Switzerland
AstraZeneca
Parexel

Completed

A Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD7594 Administered Once Daily by Inhalation in Asthmatic Subjects

Asthma

United States, Germany, South Africa, Ukraine, Japan, Hungary, Poland, Bulgaria
AstraZeneca

Completed

A Study to Assess the Effect of Particle Size of AZD7594 on Pharmacokinetics (PK) After a Single Inhaled Dose When Administered Using the Dry Powder Inhaler in Healthy Volunteers

Asthma, Chronic Obstructive Pulmonary Disease (COPD)

Germany
Sir Mortimer B. Davis - Jewish General Hospital

Terminated

Two TraCer PositROn EmiSSion Tomography ComBination for Efficacy EstimatiOn of Prostate Specific Membrane Antigen Radioligand Therapy in Patients With Metastatic Prostate Cancer (CROSSBOW)

Prostatic Neoplasms | Prostate Cancer | Metastatic Prostate Cancer | Prostate Adenocarcinoma | Metastatic Prostatic Adenocarcinoma | Metastatic Prostate Carcinoma in the Soft Tissue

Canada
Chang Gung Memorial Hospital

Unknown

Alzheimer's Disease: Clinical Investigation and Neuroimage Studies Including 18F-PM-PBB3 and 18F-florbetapir (AV-45) PET Examination (PMPBB3/AV45)

Alzheimer's Disease

Taiwan
Avid Radiopharmaceuticals
Eli Lilly and Company

Completed

Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline

Alzheimer's Disease

France, Italy, United States
Mayo Clinic
Blue Earth Diagnostics, Inc

Recruiting

18F-fluciclovine PET/MRI Imaging for the Detection of Tumor Recurrence After Radiation Injury to the Brain

Metastatic Intracranial Malignant Neoplasm | Recurrent Intracranial Neoplasm

United States
Centre Hospitalier Universitaire de Saint Etienne

Recruiting

Serotonin Role on Brain Circuits Involved in Food Avoidance in Anorexia Nervosa (SEVIALANO)

Anorexia Nervosa

France
Tammie L. S. Benzinger, MD, PhD

Withdrawn

F 18 T807 Tau PET Imaging of Frontotemporal Dementia (FTD)

Alzheimer Disease

United States
Avid Radiopharmaceuticals

Completed

18F-AV-1451 High Resolution Autopsy Study

Alzheimer's Disease

United States
Tammie L. S. Benzinger, MD, PhD

Recruiting

F 18 T807 Tau PET Imaging of Alzheimer's Disease (T807IND)

Alzheimer Disease

United States
Washington University School of Medicine

Enrolling by invitation

F 18 T807 Tau PET Imaging in Dominantly Inherited Alzheimer's Network (DIAN Project) (AV ADAD)

Alzheimer Disease

United States
Tammie L. S. Benzinger, MD, PhD

Completed

F 18 T807 Tau PET Imaging of Progressive Posterior Cortical Dysfunction (IND 123119, Protocol E) (Protocol E)

Alzheimer Disease | Progressive Posterior Cortical Dysfunction (PPCD)

United States
Avid Radiopharmaceuticals

Withdrawn

18F-AV-1451 PET Imaging in TBI

Traumatic Brain Injury

United States
Avid Radiopharmaceuticals

Terminated

Imaging Characteristics of a Follow-up 18F-AV-1451 Scan

Alzheimer's Disease

United States
Avid Radiopharmaceuticals

Completed

Imaging Characteristics of Florbetapir 18F in Patients With Frontotemporal Dementia, Alzheimer's Disease and Normal Controls.

Frontotemporal Dementia | Alzheimer's Disease

United Kingdom
University of California, San Francisco
Avid Radiopharmaceuticals; Alzheimer's Drug Discovery Foundation

Recruiting

Effects of Brain Beta-Amyloid on Postoperative Cognition

Postoperative Cognitive Dysfunction

United States
Tammie L. S. Benzinger, MD, PhD

Completed

F 18 T807 PET (Positron Emission Tomograph )Scan for HIV Infected & Uninfected

Alzheimer Disease | HIV

United States
Avid Radiopharmaceuticals

Completed

18F-AV-1451 and Florbetapir F 18 PET (Positron Emission Tomography) Imaging in Subjects at Risk for Chronic Traumatic Encephalopathy

Chronic Traumatic Encephalopathy

United States
Avid Radiopharmaceuticals

Completed

A Reader Study to Assess Accuracy and Reliability of Flortaucipir F 18 Positron Emission Tomography (PET) Scan Interpretation

Alzheimer Disease

United States
AstraZeneca

Recruiting

Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients With Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA (AJAX)

Asthma

Denmark, United States, South Africa, United Kingdom, Argentina, Vietnam, Brazil, Malaysia, Taiwan, France, Germany, Spain, Thailand, Bulgaria, Philippines, Sweden
Tammie L. S. Benzinger, MD, PhD

Withdrawn

Imaging of Brain Structural/Functional Connectivity and Amyloid and Tau Lesions in APOE4 Carriers. (Protocol_Z)

Alzheimer Disease

United States
AstraZeneca
Parexel

Completed

A Study to Evaluate the Disposition of Drug in Body and Safety After Administration of Single Inhaled Doses of Drugs Abediterol and AZD7594 Administered Alone, in Fixed Dose Combination and in Free Combination Using the Dry Powder Inhaler in Healthy Male Participants

Asthma | Chronic Obstructive Pulmonary Disease (COPD)

Germany
AstraZeneca

Completed

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7594 Inhaled Formulation in Healthy Japanese Men

Asthma | Chronic Obstructive Pulmonary Disease COPD

United States
AstraZeneca

Completed

A Phase I Study of AZD4635 in Japanese Patients With Advanced Solid Malignancies

Advanced Solid Malignancies

Japan
Insel Gruppe AG, University Hospital Bern

Completed

Diagnostic Accuracy and Performance of 18F-PSMA-1007

Prostate Cancer

Switzerland

3

Subscribe